Methylation Status as Predictor of Response to Neoadjuvant Chemotherapy in Osteosarcoma
10 Years
20 Years
Both
Sarcoma
Trial Information
Methylation Status as Predictor of Response to Neoadjuvant Chemotherapy in Osteosarcoma
OBJECTIVES:
- Determine whether methylation status predicts response to neoadjuvant chemotherapy in
samples from children and young adults with osteosarcoma.
OUTLINE: Patients are stratified according to response to neoadjuvant chemotherapy (good vs
poor).
DNA and RNA extracted from biopsy samples are analyzed for methylation changes and
transcription changes by Ligation-mediated PCR and mass-array genotyping.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosed with high-grade osteoblastic osteosarcoma
- Biopsy samples from patients who had good or poor response to neoadjuvant
chemotherapy available
- All specimens should be from post-menarchal females or age-matched males with
appendicular tumors
- Patients' clinical data including chemotherapy received, event-free survival, and
overall survival available
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Methylated status as predictor of response to neoadjuvant chemotherapy
Safety Issue:
No
Principal Investigator
Jeremy Rosenblum, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Albert Einstein College of Medicine of Yeshiva University
Authority:
United States: Federal Government
Study ID:
CDR0000702111
NCT ID:
NCT01374672
Start Date:
July 2011
Completion Date:
Related Keywords:
- Sarcoma
- osteoblastic osteosarcoma
- localized osteosarcoma
- metastatic osteosarcoma
- recurrent osteosarcoma
- Osteosarcoma
- Sarcoma
Name | Location |
|---|
